|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In a previously published study, higher levels of spleen tyrosine kinase (Syk) were observed in recurrent post-chemotherapy ovarian cancers compared to primary tumors.
|
30668583 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Significant correlations were observed between SYK and JAK pathway inhibition and tumor response.
|
30333224 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While first discovered in immunoreceptor signaling, the Syk protein kinase behaves as a tumor and metastasis suppressor in epithelial cells.
|
31817924 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, TAK-659 may provide an effective therapeutic option for treatment of LMP2A-positive EBV-associated malignancies and should be explored further in clinical trials.<b>IMPORTANCE</b> The novel SYK and FLT3 inhibitor TAK-659 prevents the enlargement of spleen and tumor development in a mouse model of EBV-associated lymphoma by counteracting the activation of cellular kinase SYK through the viral LMP2A gene by inducing cell death in tumor cells but not in nontumor cells.
|
30135222 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, in a subgroup analysis based on tumor type and test method, under-expression of SYK was positively associated with worse OS in the groups of breast cancer (BC; HR=0.51, 95% CI: 0.32-0.80, <i>P</i>=0.003), hepatocellular carcinoma (HCC; HR=0.44, 95% CI: 0.29-0.69, <i>P</i><0.001), methylation (HR=0.39, 95% CI: 0.30-0.51, <i>P</i><0.001), and quantitative reverse transcription polymerase chain reaction (HR=0.24, 95% CI: 0.09-0.65, <i>P</i>=0.005).
|
29922076 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment.
|
29401256 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of SYK and its splice variants was significantly lower in tumors with MSI, and in KRAS wild type, BRAF mutant and PTEN mutant tumors.
|
28957395 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Downstream of SHP1 and SYK-dependent counterregulation of MyD88 tyrosine phosphorylation, we have demonstrated that the scaffolding function of receptor interacting protein kinase 1 (RIPK1) and tumor growth factor-β activated kinase 1 (TAK1)-mediating signaling were required to spur inflammatory disease.
|
28410990 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<i>SYK</i> mRNA expression in tumors was higher than the normal tissues.
|
29137391 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Accordingly, B cell lymphoma-bearing mice receiving IQS019 presented a reduced tumor outgrowth characterized by a decreased mitotic index and a lower infiltration of malignant cells in the spleen, in tight correlation with downregulation of phospho-Syk, phospho-Lyn, and phospho-Btk.
|
28359287 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By CCC criteria, 6 of 8 DLBCL PDX models were B-cell receptor (BCR)-type tumors that exhibited selective surface immunoglobulin expression and sensitivity to entospletinib, a recently developed spleen tyrosine kinase inhibitor.
|
26773040 |
2016 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Among postmenopausal women, methylation of SYK was associated with increased tumor size (OR = 1.7, 95% CI: 1.0-2.7) and higher nuclear grade (OR = 2.0, 95% CI 1.2-3.6).
|
27245195 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Spleen Tyrosine Kinase (SYK) belongs to non-receptor tyrosine Kinase family, which normally expresses in epithelial breast tissues and acts as a tumor suppressor gene.
|
26889814 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Down-regulated expression of the putative tumor suppressor gene spleen tyrosine kinase (SYK) is strongly associated with the development of various cancers, including colorectal cancer (CRC).
|
25921550 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Spleen tyrosine kinase (SYK) is a non-receptor type cytoplasmic protein and a known tumor suppressor gene in breast cancer.
|
23803121 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the epigenetic landscape in mouse retinoblastoma was significantly different from human tumors and some pathways that are candidates for molecular targeted therapy for human retinoblastoma such as SYK or MCL1 are not deregulated in GEMMs.
|
23765217 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of a nonphosphorylated mutant of SYK(L) was more efficient at suppressing proliferation, colony formation, mobility, and tumor growth in HCC lines.
|
22585575 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Protein kinase SYK was expressed in all 27 samples, and its intensity significantly correlated with tumor stage.
|
22965421 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Spleen tyrosine kinase (SYK) is a non receptor type tyrosine kinase and a known candidate tumor suppressor gene in breast carcinoma.
|
22707146 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting SYK with a small-molecule inhibitor induced retinoblastoma tumour cell death in vitro and in vivo.
|
22237022 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared with peripheral T-cell lymphoma, not otherwise specified and normal γδ T cells, HSTL overexpressed genes encoding NK-cell-associated molecules, oncogenes (FOS and VAV3), the sphingosine-1-phosphatase receptor 5 involved in cell trafficking, and the tyrosine kinase SYK, whereas the tumor-suppressor gene AIM1 (absent in melanoma 1) was among the most down-expressed.
|
22510872 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Spleen tyrosine kinase (Syk), a non-receptor protein tyrosine kinase, has recently been recognized as a new candidate tumor suppressor.
|
20563729 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma.
|
19195024 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, a pharmacologic inhibitor of Syk was able to induce apoptosis of transformed B cells in vitro and led to tumor regression in vivo.
|
18981293 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transcriptional profiling analysis showed that ERp29 acts as a central regulator by upregulating a group of genes with tumor suppressive function, for example, E-cadherin (CDH1), cyclin-dependent kinase inhibitor (CDKN2B) and spleen tyrosine kinase (SYK), and by downregulating a group of genes that regulate cell proliferation (eg, FN, epidermal growth factor receptor (EGFR) and plasminogen activator receptor (uPAR)).
|
19770839 |
2009 |